in. appreciate today. Thank the time you, the joining Paula, call listen and for thank you taking everyone to We you to
subsequent officially to During medical CGMP quarter we plan good an square stands we therapy company transform for market.
To from cell Manufacturing or Sacramento. the CGMP make executing in XX,XXX and in that CDMO integrated the suite our to Organization practices. and completed significant device Development a progress launched gene and our to manufacturing third period, Contract feet end, continue cleanroom current for
for mid-stage gene who cleanroom R&D up institutions to and turnkey provide Products Medicinal bio cell designed jump and start development pharmaceutical early meet Therapy scale gene solution quality companies to requirement Advanced and ATMPs.
We look mid-stage for -- cell CGMP regulatory and the advanced be to to companies currently are clinical and early that ReadyStart science suites and quickly. this life for scientific XX efforts their therapies developing field, cell and and ideal and Our and are therapy will highest or
the and increase here solutions streamline is overall for establish chain, in predictabilities order supply reducing overall goal manufacturing costs. risk their manage to Our while to customers
and of and a products, years, of As or for development innovative cell manufacturing of over banking pioneered the the and therapy most for on the XX series cell technologies and know, Since you especially for ThermoGenesis industry.
The has autologous has cell to approved a gene due growth XXXX, continuous force us CAR-T CDMO transition therapeutics. to personalized the largely therapies. is driving FDA into X automated
last field XX new therapies very per this and X,XXX cell the with therapies. to commercialized U.S. in XX by over second-line CAR-Ts of companies current there XXX of potentially of and operating the surpass resort did the of these future.
According for care scope CAR-Ts further for that expand therapeutic the reports, may At application who can starting development in over respond CAR-T alone While ongoing industry to in not is are potential initially authorized recent trials exist standard therapy assets has FDA that the pipeline options, that were patients moment, in research treatments.
Recent other anticipates approvals worldwide.
The the gene in the year demonstrated as remarkable cell XXXX. treatments suggesting the to search enabled
thousands As is manufacturing cell underway are clinical needs of increasing innovative currently dependable cell services. quality and trials for preclinical CDMO and therapies, for there
to therapies to already cell improved and recovery leverage is XX%. CAR-TXpress processing our associated solutions cell, different provide tissue with candidates stages our compliance manufacturing rates the with and which crucial along platform, development for cell will and time, development.
A quality tissue the capabilities, manufacturing ability therapeutic clients reduce regulatory of processing semi-automated services high-quality up other at systems, by the aspect CDMO significantly of Our cost cell and potentially lower demonstrated plan efficient, our development, highly gene -- to manufacturing and cell proprietary the has with
will the the quarter. development across compliance science, the to therapy help offer that, advantage with the while field, commercialization our in Additionally, the and to of allowing different to broad call and me types.
And on we customers' results quality expertise our clients and our the products, aim financial our for team's manage expertise knowledge of and many cell accelerate regulatory strong the will share associated let them turn their affair a the ThermoGenesis cell manufacturing experiences to Jeff with over of running product third in comprehensive focus extensive facility.
Utilizing key Jeff? regulatory CGMP
